Ir direto para menu de acessibilidade.
Página inicial > Recomendation Reports
Início do conteúdo da página

Recomendation Reports

Publicado: Sexta, 11 de Setembro de 2020, 18h48 | Última atualização em Terça, 12 de Julho de 2022, 15h49 | Acessos: 5253

Find below the Health Technology Assessment Reports developed by Conitec. 

Year/Month Technology HTA Report
569 October/2020 Natalizumab Natalizumab for the treatment of relapsing-remitting multiple sclerosis after the first treatment failure
564 October/2020 Naproxen Expansion of the use of naproxen for the treatment of reactive arthritis
561 2020/September Ocrelizumab Ocrelizumab for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) as an alternative or when there is a contraindication to natalizumab
560 2020/September Dabigatran etexilate and idarucizumab Dabigatran for prevention of stroke in patients over 60 years with non-valvular atrial fibrillation who are unable to remain in the therapeutic range of international normalized ratio with warfarin and idarucizumab for reversing the anticoagulant effect of dabigatran
559 2020/September Bortezomib Bortezomib for the treatment of adult patients with previously untreated multiple myeloma who are ineligible for autologous haematopoietic stem cell transplantation
558 2020/September Bortezomib Bortezomib for the treatment of adult patients with previously untreated multiple myeloma who are eligible for autologous haematopoietic stem cell transplantation
557 2020/September Bortezomib Bortezomib for the treatment of adult patients with previously treated multiple myeloma
556 2020/September Meningococcal ACWY Meningococcal ACWY (conjugate) vaccine for adolescents aged 11–12 years in the National Vaccination Schedule
552 2020/August Risedronate 5mg tablets Exclusion of risedronate 5mg for the treatment of patients with Paget’s disease
549 2020/August Ranibizumab Ranibizumab for the treatment of diabetic macular edema (DME)
548 2020/August Automated liquid culture for detection of mycobacteria and susceptibility testing to antimicrobials used in the treatment of tuberculosis Automated liquid culture for detection of mycobacteria and susceptibility testing to antimicrobials used in the treatment of tuberculosis
547 2020/August Delamanid (Deltyba®) Delamanid for the treatment of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis
546 2020/August Bedaquiline (Sirturo®) Bedaquiline for patients with rifampicin-resistant, multidrug-resistant and extensively drug-resistant tuberculosis
545 2020/August Universal testing for hepatitis C in pregnant women in the first trimester of pregnancy during antenatal care Universal testing for hepatitis C in pregnant women in antenatal care 
544 2020/August Levothyroxine sodium Inclusion of levothyroxine sodium presentations of 12.5 and 37.5 mcg for treatment of congenital hypothyroidism
541 2020/June Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) for the first-line treatment of advanced (unresectable and metastatic) melanoma
540 2020/July Vestronidase alfa (Mepsevii®) Vestronidase alfa for the treatment of mucopolysaccharidosis type VII
539 2020/June Sirolimus Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis
538 2020/June Tofacitinib Citrate (Xeljanz®) Tofacitinib citrate for the treatment of moderate to severe ulcerative colitis in adult patients with inadequate response, loss of response or intolerance to previous treatment with conventional synthetic or biological drugs
537 2020/July Tofacitinib Citrate (Xeljanz®) Tofacitinib citrate for the treatment of moderate to severe active psoriatic arthritis in adult patients with intolerance or treatment failure with synthetic or biological disease-modifying antirheumatic drugs (DMARDs)
536 2020/August Ixekizumab (Taltz®) Ixekizumab for the treatment of active psoriatic arthritis in adult patients with an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs)
535 2020/August Ixekizumab Ixekizumab for the treatment of adult patients with moderate to severe psoriasis with treatment failure, contraindication or intolerance to adalimumab
534 2020/September Risankizumab (SKYRIZI®) Risankizumab for the treatment of adult patients with moderate to severe plaque psoriasis
533 2020/June Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Increasing the upper age limit to 75 years for allogeneic Haematopoietic Stem Cell Transplantation (HSCT) procedures
532 2020/June Human anti-hepatitis B immunoglobulin Human anti-hepatitis B immunoglobulin 1,000 IU
531 2020/June Ruxolitinib (Jakavi®) Ruxolitinib for the treatment of patients with primary myelofibrosis, postpolycythaemia vera myelofibrosis or postessential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease
526 2020/June Rifapentine plus isoniazid (3HP regimen) Rifapentine plus isoniazid for treatment of Latent Mycobacterium Tuberculosis Infection (LTBI)
525 2020/June Rifampicin 300 mg capsule, and 20 mg/mL oral suspension Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease
524 2020/March Empagliflozin and Dapagliflozin Empagliflozin and Dapagliflozin for the treatment of Type 2 Diabetes Mellitus
523 2020/March Orlistat Orlistat for weight loss in overweight or obese patients
522 2020/March Sibutramine Sibutramine for the treatment of obese patients
519 2020/March Riociguat Riociguat for inoperable or persistent/recurrent after surgical treatment Chronic Thromboembolic Pulmonary Hypertension
518 2020/April Treatment of Pseudomyxoma Peritonei Cytoreductive surgery (peritonectomy) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
517 2020/April Cytoreductive surgery (peritonectomy) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive surgery with hyperthermic chemotherapy in patients with malignant peritoneal mesothelioma
516 2020/March Newborn Screening Newborn Screening for Congenital Toxoplasmosis
515 2020/March Dolutegravir Dolutegravir for the treatment of pregnant women living with HIV
510 2020/March Baricitinib (Olumiant®) Baricitinib (Olumiant®) for patients with moderate to severe Active Rheumatoid Arthritis
509 2020/March Mirabegron Mirabegron for the treatment of storage dysfunction in patients with Neurogenic Bladder
508 2020/March Oxybutynin, Tolterodine, Solifenacin and Darifenacin Antimuscarinics (Oxybutynin, Tolterodine, Solifenacin and Darifenacin) for the treatment of Storage Dysfunction in patients with Neurogenic Bladder
507 2020/March Photodynamic Therapy Photodynamic Therapy for non-melanoma skin cancer
506 2020/February Personal Frequency Modulation System Personal frequency modulation system for hearing-impaired students at any age and at any academic level
503 2020/January Testing for prothrombin gene mutation (G202110A), protein C functional assay, protein S functional assay, anti-beta2-glycoprotein I - IgG, lupus anticoagulant Diagnostic tests for thrombophilia in pregnancy
501 2019/November Pyrazinamide 150 mg dispersible tablets Incorporation of pyrazinamide 150 mg dispersible tablets in the Brazilian National Relation of Essential Medicines (RENAME in Portuguese)
Fim do conteúdo da página